| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8193182 | SECURA | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
Feb, 2030
(5 years from now) | |
| USRE46621 | SECURA | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216982 | SECURA | Certain chemical entities, compositions and methods |
Jan, 2029
(4 years from now) | |
| US11312718 | SECURA | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
Jan, 2032
(7 years from now) | |
| US9840505 | SECURA | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Jan, 2032
(7 years from now) | |
Copiktra is owned by Secura.
Copiktra contains Duvelisib.
Copiktra has a total of 5 drug patents out of which 0 drug patents have expired.
Copiktra was authorised for market use on 24 September, 2018.
Copiktra is available in capsule;oral dosage forms.
Copiktra can be used as for the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll), for the treatment of patients with follicular lymphoma (fl).
Drug patent challenges can be filed against Copiktra from 24 September, 2022.
The generics of Copiktra are possible to be released after 17 May, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-208) | Sep 24, 2025 |
| Orphan Drug Exclusivity(ODE-209) | Sep 24, 2025 |
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2023 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 24 September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll); For the treatment of patients with follicular lymphoma (fl)
Dosage: CAPSULE;ORAL
COPIKTRA family patents
